These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7910038)

  • 1. Monoclate-P--hemofil-M study.
    Seremetis S
    Ann Hematol; 1994; 68 Suppl 3():S45-7. PubMed ID: 7910038
    [No Abstract]   [Full Text] [Related]  

  • 2. Hemofil-M study.
    Rocino A; de Biasi R
    Ann Hematol; 1994; 68 Suppl 3():S55-7. PubMed ID: 7910042
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical experience with Hemofil M in a hemophilia patient exhibiting inhibitors.
    Ingerslev J; Wallevik K
    Ann Hematol; 1991 Sep; 63(3):152-4. PubMed ID: 1932291
    [No Abstract]   [Full Text] [Related]  

  • 4. In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates.
    Kasper CK; Kim HC; Gomperts ED; Smith KJ; Salzman PM; Tipping D; Miller R; Montgomery RM
    Thromb Haemost; 1991 Dec; 66(6):730-3. PubMed ID: 1796419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrapure plasma factor VIII produced by anti-F VIII c immunoaffinity chromatography and solvent/detergent viral inactivation. Characterization of the Method M process and Hemofil M antihemophilic factor (human).
    Griffith M
    Ann Hematol; 1991 Sep; 63(3):131-7. PubMed ID: 1932287
    [No Abstract]   [Full Text] [Related]  

  • 6. A 3.5-year study of immune function in persons with hemophilia infusing recombinant factor VIII.
    Brettler D
    Ann Hematol; 1994; 68 Suppl 3():S49-50. PubMed ID: 7910039
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients--antibodies and reactions.
    Ingerslev J
    Ann Hematol; 1994; 68 Suppl 3():S79-80. PubMed ID: 8180262
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinate study.
    Gomperts E
    Ann Hematol; 1994; 68 Suppl 3():S51. PubMed ID: 7910040
    [No Abstract]   [Full Text] [Related]  

  • 9. Beriate-P study.
    Gringeri A
    Ann Hematol; 1994; 68 Suppl 3():S53-4. PubMed ID: 7910041
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates.
    Morfini M; Mannucci PM; Longo G; Cinotti S; Messori A
    Thromb Res; 1991 Feb; 61(3):285-90. PubMed ID: 1902997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients--impact on the immune and other systems.
    Poon MC
    Ann Hematol; 1994; 68 Suppl 3():S83-6. PubMed ID: 7910044
    [No Abstract]   [Full Text] [Related]  

  • 12. Lack of immune response to mouse IgG in hemophilia A patients treated chronically with Monoclate, a monoclonal antibody affinity purified factor VIII preparation.
    Davis HM; Brown SK; Nash DW; Pennetti AM; Salzman PM; Schreiber AB; Haimovich J
    Thromb Haemost; 1990 Jun; 63(3):386-91. PubMed ID: 2119524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII.
    Bray G
    Ann Hematol; 1994; 68 Suppl 3():S29-34. PubMed ID: 8180254
    [No Abstract]   [Full Text] [Related]  

  • 14. Human anti-mouse immunoglobulins in sera of patients treated chronically with monoclonal antibody-purified factor VIII.
    Haimovich J; Davis HM; Schreiber AB
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):11-5. PubMed ID: 2128852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Very-high-purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: conclusions of a prospective 3-year study. Monoclate Study Group.
    Seremetis SV
    Semin Hematol; 1993 Oct; 30(4 Suppl 5):10-3. PubMed ID: 7903480
    [No Abstract]   [Full Text] [Related]  

  • 16. Continuous infusion of monoclonal antibody-purified factor VIII.
    Weinstein RE; Bona RD; Rickles FR
    Am J Hematol; 1991 Mar; 36(3):211-2. PubMed ID: 1899966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultracentrifugal analysis of factor VIII and von Willebrand factor in therapeutic preparations.
    Aronson DL; Chang P
    Vox Sang; 1995; 69(1):8-13. PubMed ID: 7483501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor VIII safety: plasma-derived versus recombinant products.
    Gringeri A
    Blood Transfus; 2011 Oct; 9(4):366-70. PubMed ID: 21627925
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous infusion of highly purified factor VIII (Monoclate M).
    Flora S; Hambley H; Thumpston J; Clark J
    Am J Hematol; 1992 Jun; 40(2):157. PubMed ID: 1585918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.